

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceutical Pricing Authority

New Delhi, the 30<sup>th</sup> June, 2017

## ORDER

**S.O.2059 (E)-** In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30<sup>th</sup> May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 5(a) & 5(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices after excluding excise duty levied prior to GST regime, being subsumed in the GST consequent to its implementation with effect from 1.7.2017 by applying the factor of 1 on existing ceiling price, wherever applicable as specified in column (6) of the table herein below as ceiling prices exclusive of goods and Services Tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

**Table**

SI No	Medicines	Dosage form and Strength	Unit	Existing S.O. No. & Existing Date		Ceiling price (wef 1.7.2017)
				5(a)	5(b)	
(1)	(2)	(3)	(4)	5(a)	5(b)	(6)
1.	5-Fluorouracil	Injection 250 mg/5 ml	1 ml	1039(E)	01.04.2017	2.13
2.	Abacavir (A) + Lamivudine (B)	Tablet 600 mg (A)+ 300 mg (B)	1 Tablet	1039(E)	01.04.2017	86.22
3.	Abacavir (A) + Lamivudine (B)	Tablet 60 mg (A) + 30 mg (B)	1 Tablet	1008(E)	30.03.2017	19.00
4.	Acetazolamide	Tablet 250 mg	1 Tablet	1039(E)	01.04.2017	3.32
5.	Acetazolamide	Capsule 250 mg	1 Capsule	1039(E)	01.04.2017	4.11
6.	Amphotericin B – Conventional	Powder for Injection 50 mg	Each Pack	1039(E)	01.04.2017	281.05
7.	Amphotericin B – Lipid/ Liposomal	Powder for Injection 50 mg	Each Pack	1039(E)	01.04.2017	3,394.25
8.	Anti-rabies immunoglobulin	Injection 150 IU/ml	1 ml	1009(E)	31.3.2017	2,517.40
9.	Anti-rabies immunoglobulin	Injection 300 IU/ml	1 ml	1008(E)	30.03.2017	88.75
10.	Artesunate	Powder for Injection 120 mg	Each Pack	1039(E)	01.04.2017	377.59
11.	Artesunate	Powder for Injection 60 mg	Each Pack	1039(E)	01.04.2017	198.33
12.	Atazanavir (A) + Ritonavir (B)	Tablet 300 mg (A) + 100 mg (B)	1 Tablet	1039(E)	01.04.2017	93.41
13.	Azathioprine	Tablet 50 mg	1 Tablet	1039(E)	01.04.2017	9.20
14.	Baclofen	Tablet 10 mg	1 Tablet	1039(E)	01.04.2017	9.75
15.	Baclofen	Tablet 20 mg	1 Tablet	1039(E)	01.04.2017	13.43
16.	Baclofen	Tablet 5 mg	1 Tablet	1039(E)	01.04.2017	5.03

17.	Bleomycin	Powder for Injection 15 Units	Each Pack	1039(E)	01.04.2017	563.26
18.	Calcium folinate	Tablet 15 mg	1 Tablet	1039(E)	01.04.2017	37.02
19.	Capecitabine	Tablet 500 mg	1 Tablet	1039(E)	01.04.2017	119.58
20.	Chlorambucil	Tablet 5 mg	1 Tablet	1039(E)	01.04.2017	75.26
21.	Chlorambucil	Tablet 2 mg	1 Tablet	1039(E)	01.04.2017	33.49
22.	Chloroquine	Oral Liquid 50 mg/5ml	1 ml	1039(E)	01.04.2017	0.27
23.	Chloroquine	Tablet 150 mg	1 Tablet	1039(E)	01.04.2017	0.60
24.	Clindamycin	Capsule 150 mg	1 Capsule	1039(E)	01.04.2017	13.13
25.	Clindamycin	Capsule 300 mg	1 Capsule	1039(E)	01.04.2017	21.43
26.	Clindamycin	Tablet 300 mg	1 Tablet	1039(E)	01.04.2017	13.83
27.	Clofazimine	Capsule 100 mg	1 Capsule	1039(E)	01.04.2017	2.24
28.	Clofazimine	Capsule 50 mg	1 Capsule	1039(E)	01.04.2017	1.31
29.	Cyclophosphamide	Tablet 50 mg	1 Tablet	1039(E)	01.04.2017	3.68
30.	Cyclophosphamide	Powder for Injection 500 mg	Each Pack	1039(E)	01.04.2017	72.42
31.	Cyclosporine	Capsule 100 mg	1 Capsule	1039(E)	01.04.2017	93.01
32.	Cyclosporine	Capsule 50 mg	1 Capsule	1039(E)	01.04.2017	47.77
33.	Cyclosporine	Oral Liquid 100 mg/ml	1 ml	1039(E)	01.04.2017	85.77
34.	Cyclosporine	Capsule 25 mg	1 Capsule	1039(E)	01.04.2017	24.96
35.	Cyclosporine	Injection 50 mg/ml	1 ml	1008(E)	30.03.2017	244.75
36.	Cytosine arabinoside	Powder for Injection 500 mg	Each Pack	1039(E)	01.04.2017	464.71
37.	Cytosine arabinoside	Injection 100 mg/ml	Each Pack	1039(E)	01.04.2017	180.27
38.	Cytosine arabinoside	Powder for Injection 1000 mg	Each Pack	1039(E)	01.04.2017	972.31
39.	Dapsone	Tablet 100 mg	1 Tablet	1009(E)	31.3.2017	0.21414
40.	Diethylcarbamazine	Tablet 100 mg	1 Tablet	1039(E)	01.04.2017	1.28
41.	Diethylcarbamazine	Oral Liquid 120 mg/5ml	1 ml	1039(E)	01.04.2017	0.44
42.	Diethylcarbamazine	Tablet 50 mg	1 Tablet	1039(E)	01.04.2017	0.51
43.	Dopamine	Injection 40 mg/ml	1 ml	1039(E)	01.04.2017	5.12
44.	DPT + Hib + Hep B vaccine		Per 0.1 ml	1687(E)	24.05.2017	72.874
45.	DPT vaccine		Per 0.5 ml	1688(E)	24.05.2017	12.85
46.	Efavirenz	Tablet 600 mg	1 Tablet	1039(E)	01.04.2017	64.44
47.	Efavirenz	Tablet 200 mg	1 Tablet	1039(E)	01.04.2017	20.57
48.	Efavirenz	Capsule 200 mg	1 Capsule	1039(E)	01.04.2017	21.85
49.	Efavirenz	Capsule 600 mg	1 Capsule	1039(E)	01.04.2017	56.91
50.	Enoxaparin	Injection 40 mg/0.4ml	0.1 ml	1039(E)	01.04.2017	92.24
51.	Enoxaparin	Injection 60 mg/0.6ml	0.1 ml	1039(E)	01.04.2017	92.24
52.	Entecavir	Tablet 0.5 mg	1 Tablet	1039(E)	01.04.2017	72.40
53.	Entecavir	Tablet 1 mg	1 Tablet	1039(E)	01.04.2017	115.03
54.	Ethinylestradiol	Tablet 0.01 mg	1 Tablet	1039(E)	01.04.2017	2.14
55.	Ethinylestradiol	Tablet 0.05 mg	1 Tablet	1039(E)	01.04.2017	3.40
56.	Ethinylestradiol (A) + Levonorgestrel (B)	Tablet 0.03 mg (A) + 0.15 mg (B)	1 Tablet	1039(E)	01.04.2017	3.13
57.	Ganciclovir	Powder for Injection 500 mg	Each Pack	1039(E)	01.04.2017	1,531.30
58.	Ganciclovir	Capsule 250 mg	1 Capsule	1008(E)	30.03.2017	109.09
59.	Heparin	Injection 1000 IU/ml	1 ml	1334(E)	27.04.2017	14.80
60.	Heparin	Injection 5000 IU/ml	1 ml	1688(E)	24.05.2017	36.73
61.	Hepatitis B vaccine		1 ml	1688(E)	24.05.2017	71.06

62.	Hormone releasing IUD	Contains 52 mg of Levonorgestrel	1 IUD	1334(E)	27.04.2017	3,509.95
63.	Human chorionic Gonadotropin	Injection 1000 IU	Each Pack	1039(E)	01.04.2017	192.84
64.	Human chorionic Gonadotropin	Injection 5000 IU	Each Pack	1039(E)	01.04.2017	378.71
65.	Hydrocortisone	Powder for Injection 100 mg	Each Pack	1039(E)	01.04.2017	35.31
66.	Hydrocortisone	Injection 100 mg	Each Pack	1039(E)	01.04.2017	35.31
67.	Hydrocortisone	Injection 200 mg	Each Pack	1039(E)	01.04.2017	54.44
68.	Hydrocortisone	Tablet 10 mg	1 Tablet	1008(E)	30.03.2017	5.34
69.	Hydrocortisone	Tablet 5 mg	1 Tablet	1008(E)	30.03.2017	2.75
70.	Hydroxyurea	Capsule 500 mg	1 Capsule	1039(E)	01.04.2017	11.63
71.	Insulin (Soluble)	Injection 40 IU/ml	1 ml	1039(E)	01.04.2017	13.66
72.	Intermediate Acting (NPH) Insulin	Injection 40 IU/ml	1 ml	1039(E)	01.04.2017	13.66
73.	Isoflurane	Inhalation	1 ml	1039(E)	01.04.2017	9.48
74.	IUD containing Copper	As licensed	1 IUD	1688(E)	24.05.2017	260.87
75.	Lactulose	Oral Liquid 10 g/15 ml	1 ml	1039(E)	01.04.2017	1.00
76.	Lamivudine (A) + Nevirapine (B) + Stavudine (C)	Tablet 150 mg (A) + 200 mg (B) + 30 mg(C)	1 Tablet	1039(E)	01.04.2017	14.76
77.	Lamivudine (A) + Zidovudine (B)	Tablet 150 mg (A) + 300 mg (B)	1 Tablet	1039(E)	01.04.2017	18.98
78.	Lamivudine (A)+ Nevirapine (B) + Stavudine (C)	Dispersible Tablet 30 mg (A) + 50 mg (B) + 6 mg (C)	1 Tablet	1008(E)	30.03.2017	4.68
79.	Letrozole	Tablet 2.5 mg	1 Tablet	1039(E)	01.04.2017	37.00
80.	Lopinavir (A) + Ritonavir (B)	Tablet 200 mg (A) + 50 mg (B)	1 Tablet	1039(E)	01.04.2017	43.12
81.	Lopinavir (A) + Ritonavir (B)	Tablet 100 mg (A) + 25 mg (B)	1 Tablet	1008(E)	30.03.2017	22.25
82.	Melphalan	Tablet 5 mg	1 Tablet	1039(E)	01.04.2017	152.68
83.	Melphalan	Tablet 2 mg	1 Tablet	1039(E)	01.04.2017	89.02
84.	Mesna	Injection 100 mg/ml	1 ml	1039(E)	01.04.2017	15.22
85.	Methotrexate	Injection 25 mg/ml	1 ml	1039(E)	01.04.2017	43.64
86.	Methotrexate	Tablet 10 mg	1 Tablet	1039(E)	01.04.2017	11.02
87.	Methotrexate	Tablet 7.5 mg	1 Tablet	1039(E)	01.04.2017	10.52
88.	Methotrexate	Tablet 2.5 mg	1 Tablet	1039(E)	01.04.2017	4.34
89.	Methotrexate	Injection 50 mg/ml	1 ml	1039(E)	01.04.2017	36.35
90.	Methotrexate	Tablet 5 mg	1 Tablet	1039(E)	01.04.2017	7.60
91.	Methylprednisolone	Tablet 16 mg	1 Tablet	1039(E)	01.04.2017	8.44
92.	Methylprednisolone	Tablet 8 mg	1 Tablet	1039(E)	01.04.2017	4.83
93.	Methylprednisolone	Injection 40 mg/ml	1 ml	1039(E)	01.04.2017	45.41
94.	Mycophenolate mofetil	Tablet 250 mg	1 Tablet	1039(E)	01.04.2017	37.67
95.	Mycophenolate mofetil	Tablet 500 mg	1 Tablet	1039(E)	01.04.2017	74.53
96.	Nevirapine	Tablet 200 mg	1 Tablet	1039(E)	01.04.2017	13.54
97.	Nevirapine	Oral Liquid 50 mg/5ml	1 ml	1039(E)	01.04.2017	0.79
98.	Oral Rehydration Salts	As Licensed	1 ml	1039(E)	01.04.2017	0.12897
99.	Oral Rehydration Salts	As Licensed	1 gm	1039(E)	01.04.2017	0.72

100.	Penicillamine	Capsule 250 mg	1 Capsule	1039(E)	01.04.2017	13.49
101.	Premix Insulin 30:70 Injection (Regular:NPH)	Injection 40 IU /ml	1 ml	1039(E)	01.04.2017	13.66
102.	Procarbazine	Capsule 50 mg	1 Capsule	1039(E)	01.04.2017	31.37
103.	Procarbazine	Tablet 50 mg	1 Tablet	1039(E)	01.04.2017	42.74
104.	Protamine	Injection 10 mg/ml	1 ml	1039(E)	01.04.2017	8.39
105.	Pyrazinamide	Tablet 500 mg	1 Tablet	1039(E)	01.04.2017	3.84
106.	Pyrazinamide	Tablet 750 mg	1 Tablet	1039(E)	01.04.2017	5.84
107.	Pyrazinamide	Tablet 1000 mg	1 Tablet	1039(E)	01.04.2017	8.56
108.	Pyrazinamide	Tablet 1500 mg	1 Tablet	1039(E)	01.04.2017	9.47
109.	Pyrazinamide	Oral Liquid 250 mg/5ml	1 ml	1008(E)	30.03.2017	0.56
110.	Quinine	Tablet 300 mg	1 Tablet	1039(E)	01.04.2017	5.19
111.	Quinine	Injection 300 mg/ml	1 ml	1039(E)	01.04.2017	9.22
112.	Rabies Vaccine		Each Pack	1039(E)	01.04.2017	310.08
113.	Raltegravir	Tablet 400 mg	1 Tablet	1039(E)	01.04.2017	142.00
114.	Ribavirin	Capsule 200 mg	1 Capsule	1039(E)	01.04.2017	75.90
115.	Rituximab	Injection 10 mg/ml	1 ml	1039(E)	01.04.2017	717.63
116.	Somatostatin	Powder for Injection 3 mg	Each pack	1039(E)	01.04.2017	1,438.04
117.	Stavudine (A) + Lamivudine (B)	Tablet 30 mg (A) +150 mg (B)	1 Tablet	1039(E)	01.04.2017	9.03
118.	Streptomycin	Powder for Injection 750 mg	Each Pack	1039(E)	01.04.2017	7.97
119.	Streptomycin	Powder for Injection 1 gm	Each Pack	1039(E)	01.04.2017	9.46
120.	Tenofovir (A) + Lamivudine (B)	Tablet 300 mg (A) + 300 mg (B)	1 Tablet	1039(E)	01.04.2017	40.73
121.	Tenofovir (A) + Lamivudine (B) + Efavirenz (C)	Tablet 300 mg (A) + 300 mg (B) + 600 mg (C)	1 Tablet	1039(E)	01.04.2017	93.52
122.	Tetanus Toxoid	Injection	Each Pack (5 ml)	1039(E)	01.04.2017	24.89
123.	Tetanus Toxoid	Injection	Each Pack (0.5ml)	1039(E)	01.04.2017	5.64
124.	Tranexamic acid	Tablet 500 mg	1 Tablet	1039(E)	01.04.2017	15.76
125.	Tranexamic acid	Injection 100 mg/ml	1 ml	1039(E)	01.04.2017	13.55
126.	Vancomycin	Powder for Injection 1 gm	Each Pack	1039(E)	01.04.2017	431.83
127.	Vancomycin	Powder for Injection 500 mg	Each Pack	1039(E)	01.04.2017	259.74
128.	Vancomycin	Powder for Injection 250 mg	Each Pack	1333(E)	27.04.2017	201.20
129.	Vecuronium	Powder for Injection 10 mg	Each Pack	1039(E)	01.04.2017	171.56
130.	Vecuronium	Powder for Injection 4 mg	Each Pack	1039(E)	01.04.2017	82.80
131.	Vincristine	Injection 1 mg/ml	1 ml	1039(E)	01.04.2017	47.28
132.	Zidovudine	Tablet 300 mg	1 Tablet	1039(E)	01.04.2017	12.94
133.	Zidovudine	Capsule 300 mg	1 Capsule	1039(E)	01.04.2017	1.88
134.	Zidovudine (A) + Lamivudine (B) + Nevirapine (C)	Tablet 300 mg (A) + 150 mg (B) + 200 mg(C)	1 Tablet	1039(E)	01.04.2017	19.06
135.	Zoledronic Acid	Powder for Injection 4 mg	Each Pack	1008(E)	30.03.2017	3,812.10

Notes:-

- (a) The ceiling prices are applicable with effect from 1.7.2017
- (b) In respect of Gentamycin injection 40mg/ml, Dexamethasone injection 4mg/ml, Paracetamol injection 150mg/ml, Glucose Injection 5%, Glucose 10%, Sodium chloride Injection 0.9%, Glucose + Sodium chloride Injection 5%+0.9%, Water for Injection, Dicyclomine Injection 10mg/ml, Snake venom antiserum, Pheniramine Injection 22.75 mg/ml and Tetanus Toxoid injection, for any other pack size manufactured, the manufacturer shall approach NPPA for specific price approval for its formulations. The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic Acid both together corresponding to Sodium Valproate of the stated strength.
- (c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above or in S.O 412(E) dated 13.2.2017, the manufacturer shall approach the NPPA for specific price approval for its formulations along with the relevant information.
- (d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and Services tax as applicable, if any.
- (e) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and Services Tax as applicable, if any), shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013 except increase in MRP due to difference of duties and taxes on implementation of goods and Services Tax.
- (f) The manufacturers may add goods and Services tax only if they have actually paid or payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

- (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
- (m) In view of the anti profiteering clause of Goods and Services Tax Act, manufacturers are only authorized to pass additional burden of tax/ duties on scheduled formulations to consumers on account of implementation of GST for any additional tax paid/ payable by the manufacturer/ manufacturers.
- (n) While revising the ceiling price, the inputs received from pharmaceutical companies, Pharmaceutical Associations/ federations etc till 5:00 PM of 29.06.2017 have been taken into consideration. However, in cases of any inadvertent discrepancy in respect of revised ceiling price of any scheduled formulation requiring further revision, the manufacturers shall maintain their maximum retail price till the revised ceiling price is notified by NPPA.

PN/178/46/2017/F

F. No. 8(46)/2017/D.P./NPPA-Div.-II

(A P S SAWHNEY)  
Director